GLUE - NASDAQ
Monte Rosa Therapeutics, Inc.
$17.59
-0.85%Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
At a Glance
Live SnapshotMonte Rosa Therapeutics, Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Balanced capital structure with moderate leverage. Equity exceeds debt, suggesting healthy financial stability.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Monte Rosa Therapeutics, Inc. Balance Sheet
GLUE • NASDAQ
| Monte Rosa Therapeutics, Inc. Balance Sheet | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
ASSETS | |||||||
CURRENT ASSETS | |||||||
129.9M | 224.3M | 128.1M | 54.9M | 346.1M | 41.7M | 6M | |
247.2M | 147.9M | 104.3M | 207.9M | 0.0 | 0.0 | 0.0 | |
377.1M | 372.1M | 232.4M | 262.8M | 346.1M | 41.7M | 6M | |
4.6M | 173K | 505K | 7.7M | 0.0 | 0.0 | 0.0 | |
4.6M | 173K | 505K | 7.7M | 0.0 | 0.0 | 0.0 | |
0.0 | 0.0 | 0.0 | 0.0 | 2.6M | 1.8M | 514K | |
11.5M | 5.1M | 3.3M | 5.4M | 0.0 | 100K | 3.3M | |
393.2M | 377.4M | 236.2M | 275.9M | 348.7M | 43.6M | 9.8M | |
NON-CURRENT ASSETS | |||||||
50.4M | 56.3M | 62.6M | 61.9M | 12.3M | 4.6M | 1.3M | |
0.0 | 0.0 | 0.0 | 0.0 | 5.3M | 1.2M | 0.0 | |
5.1M | 5M | 4.9M | 4.6M | 0.0 | 0.0 | 0.0 | |
55.5M | 61.3M | 67.5M | 66.5M | 17.7M | 5.8M | 1.3M | |
448.7M | 438.7M | 303.8M | 342.4M | 366.3M | 49.4M | 11.1M | |
LIABILITIES | |||||||
CURRENT LIABILITIES | |||||||
3.6M | 17.2M | 11.2M | 7.9M | 6.6M | 7.1M | 3.2M | |
3.6M | 17.2M | 11.2M | 7.9M | 6.6M | 7.1M | 3.2M | |
0.0 | 7.2M | 5.3M | 3.9M | 9.2M | 1.1M | 347K | |
4.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 750K | |
0.0 | 3.7M | 3.2M | 3.1M | 0.0 | 0.0 | 0.0 | |
29.6M | 117.2M | 17.7M | 0.0 | 0.0 | 0.0 | 0.0 | |
26.7M | 11.6M | 9.3M | 10.6M | 840K | 21.1M | 0.0 | |
64.2M | 156.9M | 46.6M | 25.6M | 16.6M | 29.3M | 4.3M | |
NON-CURRENT LIABILITIES | |||||||
34.8M | 0.0 | 0.0 | 0.0 | 0.0 | 67.8M | 0.0 | |
111.3M | 16.1M | 32.3M | 0.0 | 0.0 | 1.1M | 0.0 | |
5.3M | 3.7M | 2.7M | 1.5M | 2.2M | 0.0 | 19M | |
151.4M | 58.9M | 77.9M | 45.4M | 2.2M | 68.8M | 19M | |
0.0 | 42.7M | 46M | 47M | 0.0 | 0.0 | 0.0 | |
215.6M | 215.8M | 124.5M | 71M | 18.8M | 98.1M | 23.2M | |
SHAREHOLDERS' EQUITY | |||||||
7K | 6K | 5K | 5K | 5K | 1K | 50K | |
714.1M | 664.9M | 547.9M | 503.7M | 471.6M | 404K | 0.0 | |
-477.2M | -438.6M | -365.9M | -230.5M | -122M | -48.1M | -12.2M | |
-3.8M | -3.4M | -2.7M | -1.8M | -2M | -1.1M | 0.0 | |
233.1M | 222.9M | 179.3M | 271.4M | 347.5M | -48.7M | -12.1M | |
233.1M | 222.9M | 179.3M | 271.4M | 347.5M | -48.7M | -12.1M | |
SUMMARY | |||||||
448.7M | 438.7M | 303.8M | 342.4M | 366.3M | 49.4M | 11.1M | |
247.2M | 147.9M | 104.3M | 207.9M | 5.3M | 1.2M | 0.0 | |
39.2M | 42.7M | 46M | 47M | 0.0 | 67.8M | 750K | |
-90.7M | -181.5M | -82.1M | -7.9M | -346.1M | 26.1M | -5.2M | |
65,117,761 | 65,117,761 | 65,117,761 | 65,117,761 | 65,117,761 | 65,117,761 | 65,117,761 |
SEC Filings
GLUE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 17, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 10, 2026 | February 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 09, 2026 | January 08, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 07, 2026 | January 07, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 16, 2025 | December 16, 2025 | 2025 |
Related Guides
Continue your GLUE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.